0

524400

ISHITADR

img img img img
No Data Available

ISHITA DRUGS & INDUSTRIES LTD. Share Price Update

As of the latest trading session, ISHITA DRUGS & INDUSTRIES LTD. is trading at ₹81, down by ₹-0.93 or -1.13% from its previous close. The stock has moved between ₹75.00 and ₹81.00 today. Over the past year, the stock has delivered a return of 11.24%. In the last month, it has returned 12.11%.

Investment Returns

Over 1 Month 12.11% Over 3 Months 12.26% Over 6 Months 14.36% Over 1 Year 11.24%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

ISHITA DRUGS & INDUSTRIES LTD. fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 24.20
  • P/E Ratio (TTM) 27.59
  • Beta 0.39
  • Book Value / share 37.57
  • Return on equity 8.40%
  • EPS (TTM) 2.97
  • Dividend yield [-]%
  • Net profit/quarter (Cr) 0.16
info icon alternate text

ISHITA DRUGS & INDUSTRIES LTD. Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 3.14
Operating Expense 3.05
Net Profit 0.16
Net Profit Margin (%) 5.09
Earnings Per Share (EPS) 0.52
EBITDA 0.24
Effective Tax Rate (%) 21.05
Particulars SEP 2025 (Values in Cr)
Revenue 3.07
Operating Expense 2.91
Net Profit 0.14
Net Profit Margin (%) 4.56
Earnings Per Share (EPS) 0.48
EBITDA 0.25
Effective Tax Rate (%) 36.36
Particulars JUN 2025 (Values in Cr)
Revenue 5.40
Operating Expense 5.10
Net Profit 0.30
Net Profit Margin (%) 5.55
Earnings Per Share (EPS) 1.01
EBITDA 0.44
Effective Tax Rate (%) 23.07
Particulars MAR 2025 (Values in Cr)
Revenue 4.56
Operating Expense 4.34
Net Profit 0.29
Net Profit Margin (%) 6.35
Earnings Per Share (EPS) 0.96
EBITDA 0.44
Effective Tax Rate (%) 23.68
Particulars DEC 2024 (Values in Cr)
Revenue 4.13
Operating Expense 3.88
Net Profit 0.24
Net Profit Margin (%) 5.81
Earnings Per Share (EPS) 0.80
EBITDA 0.37
Effective Tax Rate (%) 25.00
Particulars MAR 2025 (Values in Cr)
Revenue 15.00
Operating Expense 14.18
Net Profit 0.87
Net Profit Margin (%) 5.80
Earnings Per Share (EPS) 2.90
EBITDA 1.34
Effective Tax Rate (%) 25.00
Particulars MAR 2024 (Values in Cr)
Revenue 15.19
Operating Expense 14.48
Net Profit 0.75
Net Profit Margin (%) 4.93
Earnings Per Share (EPS) 2.50
EBITDA 1.19
Effective Tax Rate (%) 24.24
Particulars MAR 2023 (Values in Cr)
Revenue 12.07
Operating Expense 11.49
Net Profit 0.58
Net Profit Margin (%) 4.80
Earnings Per Share (EPS) 1.93
EBITDA 0.96
Effective Tax Rate (%) 25.64
Particulars MAR 2022 (Values in Cr)
Revenue 14.09
Operating Expense 13.15
Net Profit 0.81
Net Profit Margin (%) 5.74
Earnings Per Share (EPS) 2.69
EBITDA 1.19
Effective Tax Rate (%) 23.07
Particulars MAR 2021 (Values in Cr)
Revenue 13.95
Operating Expense 13.20
Net Profit 0.83
Net Profit Margin (%) 5.94
Earnings Per Share (EPS) 2.77
EBITDA 1.23
Effective Tax Rate (%) 20.95
Particulars MAR 2025 (Values in Cr)
Book Value / Share 36.08
ROE % 8.40
ROCE % 10.00
Total Debt to Total Equity 0.19
EBITDA Margin 8.87
Particulars MAR 2024 (Values in Cr)
Book Value / Share 33.18
ROE % 7.86
ROCE % 10.77
Total Debt to Total Equity 0.05
EBITDA Margin 7.83
Particulars MAR 2023 (Values in Cr)
Book Value / Share 30.68
ROE % 6.53
ROCE % 8.86
Total Debt to Total Equity 0.05
EBITDA Margin 7.95
Particulars MAR 2022 (Values in Cr)
Book Value / Share 28.75
ROE % 9.76
ROCE % 12.90
Total Debt to Total Equity 0.00
EBITDA Margin 8.45
Particulars MAR 2021 (Values in Cr)
Book Value / Share 26.05
ROE % 11.25
ROCE % 14.32
Total Debt to Total Equity 0.02
EBITDA Margin 8.82
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 4.83
Total Assets 16.29
Total Liabilities 16.29
Total Equity 10.78
Share Outstanding 0
Price to Book Ratio 2.18
Return on Assets (%) 5.32
Return on Capital (%) 5.91
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 4.80
Total Assets 10.80
Total Liabilities 10.80
Total Equity 9.92
Share Outstanding 0
Price to Book Ratio 1.98
Return on Assets (%) 6.92
Return on Capital (%) 7.54
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.42
Total Assets 11.40
Total Liabilities 11.40
Total Equity 9.17
Share Outstanding 0
Price to Book Ratio 1.61
Return on Assets (%) 5.06
Return on Capital (%) 5.7
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 4.68
Total Assets 11.25
Total Liabilities 11.25
Total Equity 8.59
Share Outstanding 0
Price to Book Ratio 1.44
Return on Assets (%) 7.15
Return on Capital (%) 9.36
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2.53
Total Assets 9.26
Total Liabilities 9.26
Total Equity 7.79
Share Outstanding 0
Price to Book Ratio 1.15
Return on Assets (%) 8.95
Return on Capital (%) 10.65
Particulars MAR 2025 (Values in Cr)
Net Income 1.15
Cash from Operations -3.63
Cash from Investing -0.66
Cash from Financing 4.32
Net change in Cash 0.02
Free Cash Flow -3.45
Particulars MAR 2024 (Values in Cr)
Net Income 0.98
Cash from Operations 2.12
Cash from Investing 0.13
Cash from Financing -0.86
Net change in Cash 1.38
Free Cash Flow 2.14
Particulars MAR 2023 (Values in Cr)
Net Income 0.77
Cash from Operations -2.89
Cash from Investing 0.59
Cash from Financing 1.04
Net change in Cash -1.25
Free Cash Flow -2.76
Particulars MAR 2022 (Values in Cr)
Net Income 1.04
Cash from Operations 3.07
Cash from Investing -0.93
Cash from Financing 0.00
Net change in Cash 2.14
Free Cash Flow 3.09
Particulars MAR 2021 (Values in Cr)
Net Income 1.05
Cash from Operations -0.67
Cash from Investing 2.45
Cash from Financing -0.23
Net change in Cash 1.53
Free Cash Flow -0.66
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.07 13.45 1.61 238.10 23.12 40.44
BLISS GVS PHARMA LTD. 267.45 25.57 2.49 2829.33 105.05 280.20
CIPLA LTD. 1365.25 23.19 3.35 110282.52 1165.55 1672.20
FERMENTA BIOTECH LTD. 301.30 10.02 2.26 886.76 252.15 399.00
GLAXOSMITHKLINE PHARMACEUTICAL 2424.30 40.83 24.04 41069.10 2218.00 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.07 29.88 4.33 238.10 23.12 40.44
AMRUTAJAN HEALTH LTD 548.10 27.41 4.63 1584.59 490.00 789.95
ASTRAZENECA PHARMA IND LT 8369.45 100.58 26.18 20923.63 7630.00 10653.05
BLISS GVS PHARMA LTD. 267.45 36.44 2.56 2829.33 105.05 280.20

ISHITA DRUGS & INDUSTRIES LTD. shareholding pattern

Holding
49.96%
50.03%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

ISHITA DRUGS & INDUSTRIES LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
81.00 -1.13 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 80.30
  • 26 Days 78.70
  • 10 Days 79.90
  • 50 Days 77.20
  • 12 Days 79.80
  • 100 Days 75.90
  • 20 Days 79.20
  • 200 Days 75.70
80.81 PIVOT
First Support 77.12 First Resistance 85.62 Second Support 72.31 Second Resistance 89.31 Third Support 68.62 Third Resistance 94.12
RSI 55.03 ADX 9.40 MACD 1.11 Williams % R -25.15 Commodity Channel Index (CCI) 89.60
Date 2026-05-06 Week 1241.00 Same Day 659.00 Month 761.00
1 Year 0.39 3 Year 0.44
Over 1 Month
12.11% down
Over 1 Year
11.24% down
Over 3 Months
12.26% down
Over 3 Years
16.03% down
Over 6 Months
14.36% down
Over 5 Years
22.13% down

ISHITA DRUGS & INDUSTRIES LTD. Corporate Actions

Top Gainers

Top Losers

ISHITA DRUGS & INDUSTRIES LTD. Share Price

Ishita Drugs & Industries Limited was incorporated in February, 1992 by Jagdish Agarwal. The Company is engaged in the manufacture of various Activa Pharma Ingredients, drug intermediates, fine chemicals and excipient. The company supplies its products to leading
pharmaceutical companies of India. The products are also being exported to various countries across the world. The plant has been designed and constructed to meet GMP norms.

The genesis of the Ishita Group in 1992 was the result of the entrepreneurial spirit of Mr. Jagdish Agrawal, who set up a reactive dye manufacturing unit in Ahmedabad. Buoyed by the growth of its first Venture, the Group made its maiden foray in the pharma sector in 1981 by setting up a small Bulk drugs plant at Surendranagar in Gujarat, to cater to the need of Pharma industry for Quality Products. The Bulk Drugs Industry at that point of time was highly dependent on costly imports and the growth was not achievable. The Company gradually formed a vertically integrated industry chain covering Drug Intermediates, Active Pharma Ingredients (APIs), excipients and finished dosage forms. The Group has 3 manufacturing facilities located in Gujarat, 2 for APIs and drug intermediates (at Ahmedabad and Surendranagar) and 1 for finished pharmaceutical formulations (at Mehsana).

Thereafter, the Company set up a project to manufacture bulk drugs at Sanand, in the Ahmedabad district of Gujarat with an installed capacity of 408 tpa. Commercial production commenced in Jan.'95. It established an in-house R&D laboratory which has developed a highly improved process technology for norfloxacin, which was implemented in the plant during Oct.'95.

The Company in 2009 undertook a small expansion cum-debottlenecking project; it upgraded many existing equipments.

During the year 2023-24, the GMP certification of the manufacturing facility of the Company was renewed by the regulatory authorities.

Parent organization Indian Private
NSE symbol [-]
Founded 1992
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Ishita Drugs & Industries Ltd?

Answer Field

Ishita Drugs & Industries Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 81.00 as on May 07 2026 03:29 PM.

What is the Market Cap of Ishita Drugs & Industries Ltd Share?

Answer Field

The market cap of Ishita Drugs & Industries Ltd for NSE ₹ 0.00 & for BSE ₹ 24.20 as on May 07 2026 03:29 PM.

What is the 52 Week High and Low of Ishita Drugs & Industries Ltd?

Answer Field

The 52 Week High and Low of Ishita Drugs & Industries Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 90.85 and ₹ 66.00.

What is 1 year return for Ishita Drugs & Industries Ltd?

Answer Field

The 1 year returns on the stock has been 11.24%.

What is the P/E Ratio of Ishita Drugs & Industries Ltd Share?

Answer Field

As on May 07 2026 03:29 PM the price-to-earnings (PE) ratio for Ishita Drugs & Industries Ltd share is 27.59.

What is the PB ratio of Ishita Drugs & Industries Ltd Share?

Answer Field

As on May 07 2026 03:29 PM, the price-to-book (PB) ratio for Ishita Drugs & Industries Ltd share is 37.57.

How to Buy Ishita Drugs & Industries Ltd Share?

Answer Field

You can trade in Ishita Drugs & Industries Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Ishita Drugs & Industries Ltd Share on Bajaj Broking App?

Answer Field

To buy Ishita Drugs & Industries Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Ishita Drugs & Industries Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|